Extracellular Vesicles-Based Diagnostic and Therapeutic Applications for Graft-Versus-Host Disease

WANG Zhangfei^1,2#, WANG Min^3#, WU Peipei^1,2*

( ¹Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; ² Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei 230001, China; ³ School of Biomedical Engineering, Research and Engineering Center of Biomedical Materials, Anhui Medical University, Hefei 230032, China)

Abstract:

GvHD (graft-versus-host disease) is one of the most common life-threatening complications after allo-HSCT (allogeneic hematopoietic stem cell transplantation). EVs (extracellular vesicles) are nanometer-to-micron sized biofilm vesicles containing a variety of active ingredients, such as proteins, nucleotides, lipids, and metabolites. In recent years, studies have shown that there are unique differences in serum-derived EVs components in patients after allo-HSCT, so EVs has potential diagnostic and prognostic values. In addition, cell-free therapies, represented by EVs derived from MSCs (mesenchymal stem cells), have shown significant therapeutic efficacy in pre-clinical treatment studies of GvHD. This paper not only summarizes the clinical translational value of EVs in GvHD diagnosis and treatment, but also reviews the latest progress and future prospects of engineered EVs in GvHD, in order to provide a new strategy and theoretical basis for customized and personalized combination therapy with less toxic side effects.

CSTR: 32200.14.cjcb.2024.06.0017